Please try another search
For the nine months ended 30 September 2016, Aegerion Pharmaceuticals, Inc. revenues decreased 39% to $115.6M. Net loss increased from $36.7M to $138.9M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Interest Expense, Net increase of 6% to $22.4M (expense), Other income/(expense), net) decrease of 31% to $1.1M (income).
Period Ending: | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 |
---|---|---|---|---|
Total Revenue | 35.39 | 44.53 | 35.72 | 49 |
Gross Profit | 21.55 | 21.47 | 20.75 | 36.99 |
Operating Income | -18.77 | -39.35 | -58.83 | -28.68 |
Net Income | -26.57 | -46.81 | -65.55 | -36.6 |
Period Ending: | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 |
---|---|---|---|---|
Total Assets | 353.83 | 375.88 | 400.42 | 434.2 |
Total Liabilities | 366.65 | 364.75 | 346.95 | 318.65 |
Total Equity | -12.83 | 11.12 | 53.48 | 115.55 |
Period Ending: | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -33.11 | -20.21 | -21.53 | 15.98 |
Cash From Investing Activities | -1.54 | -0.56 | -0.52 | -326.88 |
Cash From Financing Activities | 2.21 | 2.14 | -0.01 | -0.75 |
Net Change in Cash | -32.14 | -18.44 | -21.78 | -311.44 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review